

REMARKS/ARGUMENTS

Reconsideration and withdrawal of the rejection of claims 1-7 under the 1st paragraph of 35 USC 112 as failing to comply with the enablement requirement are requested. I the examiner acknowledges that CTC-96 blocks both Ian papilloma virus (BPV) from transforming cells *in vitro* and removes or reduces HPV in for skin grafts on SCID mice. However, the examiner asserts that the data presented does not somehow enable the therapeutic treatment of a subject with CTC-96 for a papilloma virus infection for example, a papilloma virus induced tumor. The Examiner asserts that the subject matter is not described in this specification in such a way as to enable one skilled in this art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. However, it is submitted that this conclusion is incorrect in light of a careful reading of the specification and drawings as presented.

One with ordinary skill in this art, based on a review of the present specification and the data were therein as well as the instructions therein is fully equipped to administer CTC-96 to a subject, human or otherwise, for the treatment of an infection with papilloma virus. The examiner appears to be questioning the probability that treatment with CTC – 96 would be effective. However, the data presented fully demonstrates the efficacy of CTC-96 for papilloma virus-induced indications. Moreover, a sustained shall amount of *in vivo* data in animals (mice) is also presented. The examiner has provided no rational basis for questioning this data or the conclusions that the applicant has drawn based on this data and as presented in the specification..

The applicant will submit shortly, a Declaration Pursuant to Rule 132 embodying the data presented in the specification as well as the data previously submitted in Exhibit A which shows the effectiveness of CTC 96 on graft size. A copy of this declaration (as yet unsigned) is submitted here with. This declaration has been forwarded to the inventor for signature and will be filed upon receipt of the executed declaration by the undersigned attorney for the reasons set forth herein as well as those set forth in the previously submitted response.

Accordingly, it is believed that this application is in condition for allowance, and favorable reconsideration and prompt notice to that effect are earnestly solicited.

Respectfully Submitted,

August 30, 2010
Date

/Jules E. Goldberg/
Jules E. Goldberg
Registration No. 24,408
Buckley Maschoff & Talwalkar LLC
50 Locust Avenue
New Canaan, CT 06940
(203) 716-2282